KDR and head and neck squamous cell carcinoma: In addition, a study of a combination of pembrolizumab with the VEGFR2 inhibitor cabozantinib for patients with PD-L1-positive, CPS >1 R/M HNSCC resulted in an impressive ORR of 45% and an overall clinical benefit rate of 90%.